Oriola Oyj (0NES) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and a warm welcome to Oriola's Q3 Results webcast. I am Tuas-Denise Örnjölm from Oriola's Investor Relations. With me today, I have our CEO Katarina Gabrielsson and CFO Mats Danielsson. After the presentations, we will open up for your questions. And as a kind reminder, we will first focus on the questions relating to Oriola's business and financial performance. And like normally, you can start to post your questions through the chat already during the presentations. As a reminder, we are also recording the webcast and the recording will be available on our website later today. And as next, we can have a look at the customary disclaimer. And now, without further ado, Katarina, please go ahead. Thank you, Toa. And welcome also on my behalf. This is the agenda for today. It's a quite traditional agenda from our side. So we'll start with the Q3 highlights, then going to the operating environment, going through the segments, then Mats will take us through the financial review before we go to the Q&A. So let's now start with quarter three highlights. And I'm really, really happy today to really standing here and saying that the sales margin and the improved adjusted EBITDA has been favorable for us this quarter. The net sales and the sales margin has growing and supported by both of our segments. The high volumes has partly been part of this one and also early vaccine deliveries in the end of the quarter three. This has resulted in higher increased sales margin and also we had some operating expenses that increased towards the end of the quarter. The net sales landed on 9% above previous year at 463 million euros. The supply chain operations have been stable during this quarter and that's a result of the implemented strategic initiatives that we ha...